Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus

British Journal of Clinical Pharmacology

Volumn 68, Issue 4, 2009, Pages 502-510

  Sidharta, Patricia N ^a   Rave, Klaus ^e   Heinemann, Lutz ^e   Chiossi, Eleonora ^d   Krähenbühl, Stephan ^b,c   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Departments of Clinical Pharmacology   (Austria)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Actelion Pharmaceuticals Italia Srl   (Italy)

^e Profil Institut fur Stoffwechselforschung GmbH   (Germany)

Author keywords

Hyperglycaemic glucose clamp; Meal tolerance test; Palosuran; Type 2 diabetes mellitus; Urotensin II; Urotensin II receptor antagonist

Indexed keywords

GLUCOSE; INSULIN; PALOSURAN; PLACEBO; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UROTENSIN II;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; MIDDLE AGED; QUINOLINES; RECEPTORS, G-PROTEIN-COUPLED; TREATMENT OUTCOME; UREA; UROTENSINS;

EID: 70449129989     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03480.x     Document Type: Article

References (44)

1. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005 36 : 197 209.
2. Mensah GA, Mokdad AH, Ford E, Narayan KM, Giles WH, Vinicor F, Deedwania PC. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 2004 22 : 485 504.
3. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999 104 : 787 794.
4. Giorgino F, Laviola L, Leonardini A. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Pract 2005 68 (Suppl. 1 S22 9.
5. Ahren B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 2005 5 : 275 286.
6. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 1996 19 : 278 286.
7. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, Tiengo A, Del Prato S. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999 48 : 99 105.
8. Boitard C. Insulin secretion in type 2 diabetes: clinical aspects. Diabetes Metab 2002 28 : 4S33 8.
9. Polonsky KS, Sturis J, Bell GI. Seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996 334 : 777 783.
10. Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health Syst Pharm 2006 63 : 929 938.
11. Evans A, Krentz AJ. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. Drug Saf 1999 21 : 7 22.
12. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994 11 : 223 241.
13. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol 2002 137 : 579 588.
14. Silvestre RA, Rodriguez-Gallardo J, Egido EM, Marco J. Inhibition of insulin release by urotensin II - a study on the perfused rat pancreas. Horm Metab Res 2001 33 : 379 381. (Pubitemid 32625709)
15. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002 359 : 1990 1997.
16. Onan D, Hannan RD, Thomas WG. Urotensin II: the old kid in town. Trends Endocrinol Metab 2004 15 : 175 182.
17. Totsune K, Takahashi K, Arihara Z, Sone M, Murakami O, Ito S, Kikuya M, Ohkubo T, Hashimoto J, Imai Y. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004 25 : 1809 1814.
18. Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, Satoh J, Oka Y. Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003 46 : 972 976.
19. Suzuki S, Wenyi Z, Hirai M, Hinokio Y, Suzuki C, Yamada T, Yoshizumi S, Suzuki M, Tanizawa Y, Matsutani A, Oka Y. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 2004 25 : 1803 1808.
20. Nicholls H. Urotensin II in human plasma. Trends Endocrinol Metab 2001 12 : 381 382.
21. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Muller C, Muller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4- hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 2004 311 : 204 212.
22. Clozel M, Hess P, Qiu C, Ding SS, Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 2006 316 : 1115 1121.
23. Sidharta PN, van Giersbergen PLM, Schaarschmidt D, Dingemanse J. Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy human subjects (Abstract). J Clin Pharmacol 2004 44 : 1192.
24. Sidharta PN, van Giersbergen PLM, Schaarschmidt D, Dingemanse J. Multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy human subjects (Abstract). Br J Clin Pharmacol 2005 60 : 677 678.
25. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krahenbuhl S, Chadha-Boreham H, Dingemanse J. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006 80 : 246 256.
26. Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet 1995 346 : 120 121.
27. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008 294 : E15 26.
28. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000 131 : 441 446.
29. Thanassoulis G, Huyhn T, Giaid A. Urotensin II and cardiovascular diseases. Peptides 2004 25 : 1789 1794.
30. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979 237 : E214 23.
31. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000 85 : 4426 4433.
32. Del Prato S. Measurement of insulin resistance in vivo. Drugs 1999 58 (Suppl. 1 3 6, discussion 75 82.
33. Nauck MA, Meier JJ, Creutzfeldt W. Incretins and their analogues as new antidiabetic drugs. Drug News Perspect 2003 16 : 413 422.
34. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003 88 : 2706 2713.
35. Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005 31 : 233 242.
36. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, Tahara H, Shoji T, Okuno Y, Nishizawa Y. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care 2003 26 : 2426 2432.
37. Taylor R, Agius L. The biochemistry of diabetes. Biochem J 1988 250 : 625 640.
38. Misciagna G, Logroscino G, De Michele G, Cisternino AM, Guerra V, Freudenheim JL. Fructosamine, glycated hemoglobin, and dietary carbohydrates. Clin Chim Acta 2004 340 : 139 147.
39. Toschi E, Camastra S, Sironi AM, Masoni A, Gastaldelli A, Mari A, Ferrannini E, Natali A. Effect of acute hyperglycemia on insulin secretion in humans. Diabetes 2002 51 (Suppl. 1 S130 3.
40. Rizzo MR, Barbieri M, Grella R, Passariello N, Barone M, Paolisso G. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. Diabetes Metab 2004 30 : 81 9.
41. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000 10 : 229 237.
42. Watson AM, Lambert GW, Smith KJ, May CN. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 2003 42 : 373 379.
43. Langham RG, Kelly DJ, Gow RM, Zhang Y, Dowling JK, Thomson NM, Gilbert RE. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 2004 44 : 826 831.
44. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003 104 : 1 5.